Need Help?

Efficacy of CDK4/6i in preclinical models of malignant pleural mesothelioma

Assessment of antitumor activity of CDK4/6 inhibitors using in vitro and in vivo preclinical models of MPM using RNA-sequencing. We also include the genomic characterization (whole exome sequencing) of patient-derived cell lines used in the in vitro experiments.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001007737 Illumina HiSeq 4000 12
EGAD00001007738 Illumina HiSeq 4000 10
EGAD00001007739 Illumina HiSeq 4000 17
Publications Citations
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Br J Cancer 125: 2021 1365-1376
10